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Abstract
Background: The fibroblast growth factor (FGF) family is essential to normal heart development. Yet, its contribution to
cardiomyocyte differentiation from stem cells has not been systemically studied. In this study, we examined the
mechanisms and characters of cardiomyocyte differentiation from FGF family protein treated embryonic stem (ES) cells and
induced pluripotent stem (iPS) cells.
Methodology/Principal Findings: We used mouse ES cells stably transfected with a cardiac-specific a-myosin heavy chain
(aMHC) promoter-driven enhanced green fluorescent protein (EGFP) and mouse iPS cells to investigate cardiomyocyte
differentiation. During cardiomyocyte differentiation from mouse ES cells, FGF-3, -8, -10, -11, -13 and -15 showed an
expression pattern similar to the mesodermal marker Brachyury and the cardiovascular progenitor marker Flk-1. Among
them, FGF-10 induced cardiomyocyte differentiation in a time- and concentration-dependent manner. FGF-10 neutralizing
antibody, small molecule FGF receptor antagonist PD173074 and FGF-10 and FGF receptor-2 short hairpin RNAs inhibited
cardiomyocyte differentiation. FGF-10 also increased mouse iPS cell differentiation into cardiomyocyte lineage, and this
effect was abolished by FGF-10 neutralizing antibody or PD173074. Following Gene Ontology analysis, microarray data
indicated that genes involved in cardiac development were upregulated after FGF-10 treatment. In vivo, intramyocardial co-
administration of FGF-10 and ES cells demonstrated that FGF-10 also promoted cardiomyocyte differentiation.
Conclusion/Significance: FGF-10 induced cardiomyocyte differentiation from ES cells and iPS cells, which may have
potential for translation into clinical applications.
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Introduction
Heart failure is a leading cause of morbidity and mortality
throughout the world [1,2]. The dominant cause of heart failure is
the loss of myocardium due to coronary artery disease. In the
ischemic heart, cardiomyocytes (the contracting heart muscle cells)
undergo necrosis, autophagy, and apoptosis, ultimately leading to
scar formation. Therefore, strategies to replace damaged cardio-
myocytes may prevent heart failure and save lives.
Stem cell therapy is an attractive approach for cardiomyocyte
replacement. Recently, mesenchymal stem cells [3], cardiac
progenitor cells [4], embryonic stem (ES) cells [5], and induced
pluripotent stem (iPS) cells [6] have been reported to be capable of
cardiomyocyte differentiation. Amongst them, ES cells and iPS
cells may have the best potential. However, the conventional
protocol using the hanging drop method to induce cardiac
differentiation from ES cells or iPS cells is extremely inefficient [7–
9], which is a severe obstacle to the use of ES/iPS cells for
cardiomyocyte replacement therapy. Accordingly, studies to
dissect the molecular pathways mediating ES/iPS cell differenti-
ation into the cardiomyocyte lineage are essential.
The fibroblast growth factor (FGF) family is composed of
multifunctional proteins regulating organogenesis, tissue develop-
ment, and stem cell differentiation. Recent studies have also shown
a crucial function of the FGF family during cardiogenesis [10,11].
For example, the expression of FGF-2 stimulates proepicardial cell
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FGF receptor (FGFR)-2-III null mice have abnormal heart
positioning [12]. Nevertheless, the function of FGFs in ES/iPS
cell cardiomyocyte differentiation remains largely unknown. In
this study, we used mouse ES cells stably transfected with a
cardiac-specific a-myosin heavy chain (aMHC) promoter-driven
enhanced green fluorescent protein (EGFP) and mouse iPS cells to
investigate cardiomyocyte differentiation. We focused on the
expression pattern of FGFs during ES/iPS cell differentiation and
carried out experiments to explore the role of FGFs in
cardiomyocyte differentiation.
Results
Temporal expression profile of FGF members during ES
cell cardiomyocyte differentiation
Cardiomyocyte differentiation of ES cells underwent several
stages denoted by the temporal expression of specific markers
(Figure 1A, and 1B). Undifferentiated ES cells (day 0) highly
expressed Oct4, which gradually diminished after differentiation
into ectodermal, mesodermal, and endodermal lineages. Meso-
dermal cells expressed Brachyury from day 2 to day 4, and
cardiovascular progenitors, the offspring of mesodermal cells,
expressed Flk-1 from day 4 to day 6. Cardiac precursors started to
appear on day 4, indicated by the expression of Gata4.
Cardiomyocytes, as denoted by the expression of the cardiac
structural markers aMHC and cardiac troponin-T, can only be
detected by flow cytometry after day 6 of treatment. However, the
more mature cardiomyocyte marker, cardiac troponin-I, was not
detected until day 8.
One logical approach to increase the proportion of ES cell-
derived cardiomyocytes is to take action at an early stage in the
differentiation process by augmenting the ratio of ES cells
committed to the mesodermal and cardiovascular progenitor
lineages. Therefore, members of the FGF family that have a high
potential to generate cardiomyocytes may be expressed early in the
differentiation process when cells are at the stages of mesodermal
and cardiovascular progenitors, that is, from day 2 to day 4.
Screening of the temporal expression profile of FGF genes
revealed that FGF-3, FGF-8, FGF-10, FGF-11, FGF-13 and
FGF-15 were mostly expressed from day 2 to day 4 (Figure 1C).
Among them, the exogenous FGF-10 recombinant protein was the
most effective in increasing cardiomyocyte differentiation from ES
cells by two-fold (Figure 1D).
FGF-10 is crucial to cardiomyocyte differentiation from ES
cells
Certain growth factors, Wnt-3a being a notable example, are
well known to act both stimulatory and inhibitory to cardiomy-
ocyte differentiation depending on the application time during the
differentiation process [13]. We found that FGF-10 only enhanced
cardiomyocyte differentiation when applied at day 2 or day 4
(Figure 2A, and 2B), which coincided with the expression pattern
of the FGF-10 gene (Figure 1C). Also, the stimulatory effect of
FGF-10 was concentration-dependent, and immunoblotting
confirmed the increased expression of three structural proteins
cardiac tropomyosin (Tpm), cardiac troponin-T (cTnT), and
cardiac troponin-I (cTnI) (Figure 2B, 2C and 2D). EGFP-positive
cells were observed to have more synchronized beating in the
FGF-10 treatment group through real-time imaging of the
contractile embryoid bodies (Video S1, S2, S3, S4) as well as a
more obvious sarcomeric structure through confocal imaging using
antibodies against cTnI, cTnT, and Tpm (cTnI data shown in
Figure 2G, other data not shown). Our data showed that the
cardiomyocyte differentiation ratio increased over time and
reached ,14% in the FGF-10 treated group on day 8 and
,20% if we prolonged the differentiation time to 14 days (Figure
S1A). The group treated with 100 ng/ml of FGF-10 had an
optimal cardiomyocyte differentiation ratio that was significantly
higher than the group treated with 10 ng/ml of FGF-10
(Figure 2B). Therefore, 100 ng/ml of FGF-10 was used for all
subsequent treatments.
Not only does FGF-10 promote cardiomyocyte differentiation, it
is crucial during normal cardiomyocyte differentiation process in
ES cells. The importance of FGF-10 was demonstrated by the
finding that both FGF-10 neutralizing antibody, which inhibited
the activation of Akt by FGF-10, and FGF-10 short hairpin RNA
(shRNA) blocked cardiomyocyte differentiation without affecting
the cell number (Figure 2E, 2F and Figure S2). Moreover, FGF-10
did not influence the ES cell cycle (data not shown), indicating that
the FGF-10 response was specific to cardiomyocyte differentiation
and not a consequence of ES cell proliferation increase or ES cell
apoptosis decrease.
To gain more insight on the effect of FGF-10 in the
cardiomyocyte differentiation process, we examined the expression
pattern of several markers using cells treated with FGF-10
recombinant protein and shRNA for knockdown (Figure S3).
From the semi-quantitative PCR results, FGF-10 increased the
expression of Brachyury, Flk-1 and mature cardiac markers
aMHC, cTnI and cTnT. Interestingly, FGF-10 knockdown
resulted in downregulation of Flk1, Gata4, aMHC, cTnT, and
cTnI, but not Brachyury. Together, these results demonstrate that
FGF-10 may induce the mesodermal and cardiogenic gene
expression. However, the increased mesoderm differentiation by
FGF-10 is sufficient but may not be required for cardiac
differentiation. In addition to mesoderm induction, FGF-10 also
promoted expression of the ectoderm genes at early stages (day 3
to day 5) and that of the endoderm genes in later differentiation
process (day 5 to day 7) (Figure S1B, S1C, and S1D)
Response to FGF-10 is mediated via FGF receptors
Members of the FGF family, with the exception of FGF-11, -12,
-13 and -14, exert their functions via FGF receptors (FGFRs) [14].
Genes encoding all seven isoforms of FGFR RNA, as well as
FGFR-1 and FGFR-2 proteins were expressed during the
cardiomyocyte differentiation process of ES cells (Figure 3A, 3B
and 3C). The small molecule FGFR-specific inhibitor, PD173074,
diminished the degree of cardiomyocyte differentiation with or
without FGF-10 stimulation, and without altering the cell number
(Figure 3D, 3E and data not shown). FGFR inhibition also
downregulated the expression of the cardiomyocyte-specific genes
Gata4, Mlc1a, Mlc2v, cTnT and cTnI (Figure 3F). FGF-10 is
known to primarily activate FGFR-2 with little stimulatory action
on FGFR-1 [15]. To determine which FGFR isoforms contribute
to the FGF-10-mediated cardiomyocyte differentiation response,
shRNA interference was used. FGFR-1 and FGFR-2 shRNA
reduced cardiomyocyte differentiation from both non-stimulated
and FGF-10-stimulated ES cells, while the scramble control vector
had no effect (Figure 3G). Reduced cardiomyocyte differentiation
was more obvious in the FGFR-2 knockdown group than that in
FGFR-1 knockdown. Therefore, FGFR-2 may play a more
important role in FGF-10 promoted cardiomyocyte differentiation
from ES cells. To prove that the increased percentage of
cardiomyocyte differentiation was specifically due to FGFR-2
activation by FGF-10 rather than by other FGFR-2 activators, ES
cells were treated with FGF-7 and evaluation of cardiomyocyte
differentiation showed no significant difference from that of the
control (Figure 1D).
FGF10 Cardiac Differentiation
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FGF-10 is also apparent in iPS cells
Research on iPS cells is gaining momentum because of their
accessibility, similar pluripotency, and fewer ethical concerns than
ES cells [16,17]. While iPS cells have been shown to differentiate
into cardiomyocytes for cardiac repair, the cardiomyocyte differ-
entiation ratio is as low as that of ES cells [18]. It is thus instructive
to examine the effects of FGF-10 on cardiomyocyte differentiation
in iPS cells.
Similar to its effect on ES cells, FGF-10 doubled cardiomyocyte
differentiation from iPS cells (Figure 4A, and 4B), while FGF-10
inhibition by its neutralizing antibody and FGFR inhibition by the
Figure 1. Gene expression profiles of FGF members during cardiomyocyte differentiation from embryonic stem cells. A, Schematic
presentation of the cardiomyocyte differentiation process showing the intermediate stages denoted by the expression of specific marker genes. B,
RT-PCR results showing temporal expression patterns of these marker genes on days 2 (D2), 4 (D4), 6 (D6) and 8 (D8) of hanging drop cultivation
(n=3). Purified embryonic stem cell-derived cardiac precursors (CP) and neonatal (1 – 2 days after birth) cardiomyocytes (CM) served as controls. C,
RT-PCR data showing temporal expression patterns of FGF members (n=3). Note that FGF-3, FGF-8, FGF-10, FGF-11, FGF-13, and FGF-15 are mainly
expressed during the mesodermal and cardiovascular progenitor stages. D, Cardiomyocyte differentiation following treatment with FGF-3, FGF-7,
FGF-8, FGF-10, FGF-11, FGF-13, and FGF-15 (n=3). FGF-2 served as a control. ***p,0.001, NS=not significant.
doi:10.1371/journal.pone.0014414.g001
FGF10 Cardiac Differentiation
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tion (Figure 4C, and 4D). Therefore, the FGF-10-FGFR axis is
essential to activate iPS cells into the cardiomyocyte lineage, and
FGF-10 is a promising candidate in augmenting this process.
FGF-10 modulates the expression of genes that regulate
cardiogenesis
FGF-10 significantly upregulated cardiomyocyte differentiation
on day 2 rather than day 4 when FGF-10 was highly expressed
(Figure 2B). We anticipated the effect of FGF-10 on cardiomyo-
cyte differentiation is to activate differentiation of mesodermal
lineages. To shed light on how FGF-10 governs the course of
cardiomyocyte differentiation, the global gene expression was
profiled by Affymetrix Mouse Genome 430 2.0 Array. As
predicted, the mesodermal markers Brachyury, Goosecoid, and
surprisingly, the early cardiac marker, Mesp1 were upregulated
upon FGF-10 treatment (Figure 5B and Table S1). Results from
Gene Ontology analysis suggested that the genes involved in
cardiac developmental pathways were induced by FGF-10. In
addition, the effect of FGF-10 was not limited to the cardiac
lineage. Gene Ontology also revealed the role of FGF-10 in cell
adhesion and tissue development such as in neurogenesis, blood
vessel morphogenesis, and spermatogenesis (Figure 5A).
FGF-10 enhances cardiomyocyte differentiation from ES
cells in vivo
As a proof of concept, the cardiomyocyte differentiation response
to FGF-10 was examined in an in vivo setting (Figure 6A). Self-
assembling peptide nanofiber hydrogels were used to form a defined
intramyocardial microenvironment where FGF-10 and embryoid
bodies (EBs) were injected into [19]. FGF-10 significantly enhanced
EGFP-cTnT double positivecells per totalcellcount at the injection
area (Figure 6B and 6C). The number of the double positive EGFP-
cTnT cells was decreased in the FGF-10 mixed with PD173074
compound group. This indicates that FGF-10 can promote cell
differentiation into cardiomyocytes which expressed late stage
cardiac markers such as cTnT though clear sarcomeric structure
cannot be observed, possibly due to the limitation of cell spreading
in the injected hydrogel microenvironment. Therefore, FGF-10
increases cardiomyocyte differentiation of ES cells in vivo.
Discussion
T h em a j o rc h a l l e n g eo fu s i n gE Scell-based cardiomyocyte
replacement therapy is the inefficiency of the conventional protocol
to generate cardiomyocytes [8,9]. In the present study, we identified
FGF-10 as a key factor in ES/iPS cell differentiation into cardiomyo-
cytes. FGF-10 doubled the proportion of ES/iPS cells entering the
cardiomyocyte lineage. The FGFR-1 and FGFR-2 were required for
the FGF-10 effect. These findings suggest that FGF-10 may serve as a
target in developing novel therapies for cardiac regeneration.
To explore the molecular mechanisms controlling ES cell
differentiation into cardiomyocytes, we used an aMHC-based
reporter system to profile the temporal gene expression of cardiac
markers during ES cell differentiation. Previously, other groups
used the Nkx2.5 reporter system to investigate stem cell
differentiation into cardiomyocytes [20–22]. Because Nkx2.5 is
an earlier marker or cardiac precursor cells than aMHC [20], a
reporter system using Nkx2.5 may not be as representative as
aMHC. Cells expressing Nkx2.5 may differentiate into lineages
other than cardiomyocytes, such as conduction system cells,
endothelial cells, and vascular smooth muscle cells [21,22].
We focused on the FGF family members and identified the
expression pattern of several FGFs at the mesodermal and
cardiovascular progenitor stages, around two to three days after
EB formation. Among the candidates, only FGF-10 consistently
enhanced ES cell and iPS cell differentiation into cardiomyocytes.
Interestingly, the time of FGF-10 addition was critical for cardiac
induction; there was no effect on cardiomyocyte differentiation
when we applied FGF-10 at day 0, but there was a ,2-fold
increase of cardiomyocyte differentiation when applying FGF-10
at day 2 or day 4. This suggests that FGF-10 interacts with
mesodermal cells and commits them into precursors of the
cardiomyocyte lineage. While we showed that FGF-10 may affect
the cardiomyocyte lineage, its effect on other cardiovascular
lineages is unclear and requires further investigation. Because of
the low efficiency of ES cell-derived cardiomyocytes, the difficulty
of purification is another obstacle that must be overcome.
FGF signaling is triggered through FGFR activation [14]. In our
study, FGFR-1 and FGFR-2 were expressed during ES cell
cardiomyocyte differentiation. PD173074, an inhibitor of FGFRs,
and FGFR-1, FGFR-2 shRNA reduced ES cell cardiomyocyte
differentiation, thus demonstrating that the FGF-FGFR signaling
pathway is critical in the control of ES/iPS cell differentiation into
cardiomyocytes [12,23]. Reduced cardiomyocyte differentiation
was much more significant in the FGFR-2 knockdown group than
that in FGFR-1 knockdown. Thus, our findings suggest that
FGFR-2 may be a potential biomarker to identify cells committed
to cardiac lineages. Therefore, in the future we may pursue a
genetic fate-mapping approach to establish that FGF-10-FGFR-2
signaling plays a pivotal role in ES/iPS cell cardiac differentiation.
iPS cells are known to differentiate into cardiomyocytes
[17,24,25]. The main advantages of iPS cells are the absence of
an immune response and minimal ethical concerns, making these
cells a powerful tool for stem cell therapy. Unfortunately, iPS cell
cardiomyocyte differentiation ratio is extremely inefficient for
therapies, much like ES cells [26]. Therefore, we also set out to test
whether FGF-10 augments the ratio of iPS cell differentiation into
cardiomyocytes. Interestingly, our results showed that FGF-10 and
its inhibition had similar effects on iPS cells and ES cells. Our data
revealed that the function of FGF-10 in regulating stem cell
cardiac differentiation is similar in both ES cells and iPS cells.
We performed microarray in search for a possible mechanism of
how FGF-10 promotes cardiomyocyte differentiation from ES
cells. The enhancement of FGF-10 on cardiomyocyte differenti-
ation applied on day 2 better than on day 4 when the endogenous
FGF-10 highly expressed indicated the possibilities of direct or
indirect interaction of regulators involved in mesodermal lineages.
Array data revealed mesodermal markers such as Brachyury,
Figure 2. FGF-10 enhances cardiomyocyte differentiation. A, Protocol to determine the effect of FGF-10 application. B, Cardiomyocyte
differentiation of embryonic stem (ES) cells following FGF-10 administration at different times (n=3). Control, no treatment. C, Representative results
of flow cytometry for analysis of ES cell differentiation at different time points of FGF-10 treatment. Green boxes indicate EGFP-positive
cardiomyocytes (percentages indicated on each panel, n§3). Control, no treatment. D, Immunoblot analysis of mature cardiac markers—cardiac
tropomyosin (Tpm), cardiac troponin T (cTnT) and cardiac troponin I (cTnI) in embryoid bodies (n=3). Control, no treatment. E, Differentiation and
cell counts of ES cells with FGF-10 neutralizing antibody on day 6 (n=3). Control, no treatment. *p,0.05, **p,0.01, ***p,0.001. F, Cardiomyocyte
differentiation with treatment of FGF-10 short hairpin RNA (shRNA, n=3). Control, cells treated with a scramble shRNA. ***p,0.001. G, Confocal
imaging of disassociated embryoid bodies using the antibody against cardiac troponin I. Control, no treatment.
doi:10.1371/journal.pone.0014414.g002
FGF10 Cardiac Differentiation
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PLoS ONE | www.plosone.org 6 December 2010 | Volume 5 | Issue 12 | e14414Figure 3. The FGF-10 response is mediated via FGF receptors. A, RT-PCR results showing gene expression of all 7 isoforms of FGF receptors
(FGFRs) during embryonic stem cell cardiomyocyte differentiation (n=3). B-C, Photomicrographs of embryonic bodies (EBs) stained for FGFR-1
(B) and FGFR-2 (C) at the indicated days. Control, without first antibody. D, Cardiomyocyte differentiation in the presence of the specific small
molecule inhibitor of FGFR, PD173074, alone and along with FGF-10. (n=3). E, Cardiomyocyte differentiation in response to FGF-10 and PD173074 at
the indicted times in hanging drop culture. F, RT-PCR data for the expression of cardiomyocyte-specific genes following treatment with FGF-10 or
FGFR inhibitor. Control, GAPDH. G, Cardiomyocyte differentiation in the treatment of FGFR-1, FGFR-2 short hairpin RNA (shRNA, n=3). Control, cells
treated with a scramble shRNA. *p,0.05, ***p,0.001.
doi:10.1371/journal.pone.0014414.g003
Figure 4. FGF-10 also augments cardiomyocyte differentiation from induced pluripotent stem cells. A, The induced pluripotent stem
(iPS) cell line (Nanog promoter-driven EGFP) used in the present study. B–D, Results of cardiomyocyte differentiation from iPS cells in the treatment
of FGF-10 (B), FGF-10 neutralizing antibody (C) or FGFR inhibitor PD173074 (D). Control, no treatment. *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0014414.g004
FGF10 Cardiac Differentiation
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upregulated following FGF-10 treatment. Gene ontology analysis
also indicated that FGF-10 may act through BMP, TGF-b, Wnt-
b-catenin, Notch, and VEGF signaling to induce cardiomyocyte
differentiation, although the specific mechanisms have yet to be
determined. FGF-10 not only promoted cardiomyocyte differen-
tiation via activating mesodermal lineages at early stage of
differentiation but also increased the expression of cTnT, and
cTnI, two mature cardiac markers, in ES cell-derived cardiomy-
ocytes at later differentiation stage.
To explore the in vivo role of FGF-10 in cardiomyocyte
differentiation, we injected FGF-10 incubated with peptide
nanofibers into the myocardium. Interestingly, similar to in vitro
results, FGF-10 increased the ratio of EGFP-positive cells.
However, while these EGFP-positive cells co-expressed cTnT,
the indication that these cells turned into mature cardiomyocytes is
yet to be confirmed because the sarcomeric structure is not
obvious. Our present two-week study falls short in answering some
pending concerns, such as teratoma formation and immune
response to FGF-10-stimulated ES cell-based therapy. A long term
in vivo study is required to verify the roles of FGF-10-guided ES cell
differentiation in aiding cardiac repair after myocardial infarction.
In conclusion, we discover that FGF-10 is a novel regulator of
cardiomyocyte differentiation from ES cells and iPS cells. Our
results not only help in understanding the molecular mechanisms
mediating ES/iPS cell cardiac differentiation, but also have the
potential for translation into clinical applications.
Materials and Methods
Ethics Statement
All animal research procedures were approved by the National
Cheng Kung University Animal Care and Use Committee. The
investigation conformed to the Guide for the Care and Use of Laboratory
Figure 5. FGF-10 modulates the expression of cardiac related genes and pathways. A, Gene ontology process network analysis showing
predicted functions of FGF-10 mediated upregulated genes. (p-value x0.01). B, Gene validation using quantitative real-time PCR, *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0014414.g005
FGF10 Cardiac Differentiation
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Publication No. 85-23, revised 1996).
Culture of mouse ES-aMHC-EGFP cells and
cardiomyocyte differentiation induction
Mouse ES-aMHC-EGFP cells were obtained by transfection of
the a-myosin heavy chain (MHC) promoter-driven enhanced
green fluorescent protein (EGFP) reporter into the CGR8 ES cell
line [8]. For normal maintenance, ES cells were cultured in
Glasgow Minimum Essential Medium (Sigma, St. Louis, MO)
supplemented with 15% knockout serum replacement (Invitrogen,
Carlsbad, CA), 1% non-essential amino acids (Invitrogen), 1 mM
sodium pyruvate (Invitrogen), 1% penicillin/streptomycin (Invi-
trogen), 0.1 mM -mercaptoethanol (Sigma) and 1000 U/mL
leukemia inhibitory factor (Chemicon, Temecula, CA). To initiate
cardiomyocyte differentiation (day 0), ES cells were cultured in
hanging drops of 400 cells per 20 mL of differentiation medium
(composition identical to maintenance medium except without
leukemia inhibitory factor and 10% fetal bovine serum replacing
knockout serum replacement) to form EBs. On day two, EBs were
transferred into fresh differentiation medium for suspension
cultivation in non-adhering petri dishes. To screen the effects of
FGF members on cardiomyocyte differentiation, FGF-2, FGF-3,
FGF-10 (R&D Systems, Minneapolis, MN), FGF-11, FGF-13
(both from Abnova, Taipei, Taiwan) and FGF-7, FGF-8, FGF-15
(all from PeproTech, Rocky Hill, NJ) recombinant proteins were
applied on day 2 at 100 ng/ml.
Culture of mouse iPS cells
Mouse iPS-MEF-Ng-20D-17 cells were obtained from the Cell
Bank, Riken BioResource Center (Tsukuba, Japan). These cells
contained a Nanog promoter-driven EGFP reporter [31]. Mouse
iPS cells were cultured with or without mouse embryonic
fibroblasts as a feeder layer. The procedures of maintenance and
cardiomyocyte differentiation initiation of iPS cells were otherwise
identical to ES cells as described above.
Figure 6. FGF-10 promotes cardiomyocyte differentiation from embryonic stem cells in vivo.A , Schematic illustration of the
intramyocardial administration of embryonic stem (ES) cells and peptide nanofibers (NF). B, Statistical summary of EGFP-cTnT double positive cells
per total cell count from images such as in C (n=4; **p,0.01). C, Photomicrographs of ES cells from hearts injected with cells and NF only (upper
panel), along with FGF-10 (middle panel) and with FGF-10 plus PD173074 (lower panel). Also shown are cardiomyocytes stained for EGFP (green),
cardiac Troponin-T (cTnT, red) and DAPI (blue). Note the co-localization of EGFP and cTnT (yellow).
doi:10.1371/journal.pone.0014414.g006
FGF10 Cardiac Differentiation
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RNA was extracted from ES cells, EBs at various time points
(day 2, day 4, day 6 and day 8), ES cell-derived cardiac precursors
and neonatal mouse cardiomyocytes using Trizol reagent
(Invitrogen Carlsbad, CA) according to the manufacturer’s
protocol. Semi-quantitative reverse transcription-polymerase
chain reaction (RT-PCR) was subsequently performed. The
primer sequences used for RT-PCR were as follows:
GAPDH, forward: 59-AACGACCCCTTCATTGAC-39, reverse:
59-TCCACGACATACTCAGCAC-39;
Oct4, forward: 5-9CACGAGTGGAAAGCAACTCA-39, re-
verse: 59AGATGGTGGTCTGGCTGAAC-39;
Brachyury, forward: 59-GCTCATCGGAACAGCTCTCCAA-
CC-39, reverse:
59-GGAGAACCAGAAGACGAGGACGTG-39;
Flk-1, forward: 59-GCTTTCGGTAGTGGGATGAA-39, reverse:
59-GGAATCCATAGGCGAGATCA-39;
Gata4, forward: 59-GCAGCAGCAGTGAAGAGATG-39,r e v er s e :
59-GCGATGTCTGAGTGACAGGA-39;
aMHC, forward: 59-GAGGACCAGGCCAATGAGTA-39, re-
verse:
59-GCTGGGTGTAGGAGAGCTTG-39;
Cardiac troponin I (cTnI), forward: 59-CTCCTCTGCCAAC-
TACCGAG-39, reverse:
59-CTCAAACTTTTTCTTGCGGC-39;
Cardiac troponin T (cTnT), forward: 59-ATCCCCGATGGA-
GAGAGAGT-39, reverse:
59-TTCCCACGAGTTTTGGAGAC-39;
Mlc1a, forward: 59-CCTCAAGGACTCTGCCTTTG-39,r e v e r s e :
59-TCTTCTCTCCCAGGGTAGCA-39;
Mlc2v, forward: 59-AGCCTTCACAATCATGGACC-39,r e v e r s e :
59-CCTCCCTGCTTGTGTGGTCA-39;
FGF-1, forward: 59-GGTTCAACCTGCCTCTAGGA-39,r e v e r s e :
59-ATAAAAGCCCTTCGGTGTCC-39;
FGF-2, forward: 59-TATCAAGGGAGTGTGTGCCA-39,r e v e r s e :
59-TATGGCCTTCTGTCCAGGTC-39;
FGF-3, forward: 59-CTTCGGATCACTACAACGCA-39, reverse:
59-GGGCAGGAAGAGAGAGGACT-39;
FGF-4, forward: 59-CGAGGGACAGTCTTCTGGAG-39, re-
verse:
59-GACACTCGGTTCCCCTTCTT-39;
FGF-5, forward: 59-GTCTTCTGCCTCCTCACCAG-39,r e v e r s e :
59-GAAGTGGGTGGAGACGTGTT-39;
FGF-6, forward: 59-AATTGGGAAAGCGGCTATTT-39,r e v e r s e :
59-CCCGTCCATATTTGCTCAGT-39;
FGF-7, forward: 59-CAAACGGCTACGAGTGTGAA-39, re-
verse:
59-TAAGGCAACGAACATTTCCC-39;
FGF-8, forward: 59-TTGCACTTGCTGGTTCTCTG -39,
reverse:
59- ACTCGGACTCTGCTTCCAAA -39;
FGF-9, forward: 59-TTCCCCAACGGTACTATCCA-39, re-
verse:
59-CTTTGTCAGGGTCCACTGGT-39;
FGF-10, forward: 59-TTTTTGGTGTCTTCGTTCCC-39,
reverse:
59-CTGACCTTGCCGTTCTTCTC-39;
FGF-11, forward: 59-GTCGCTTTAAGGAGTGCGTC-39,
reverse:
59-CACTGTGGAGAGAAGGCTCC-39;
FGF-12, forward: 59-TTCCTGTAGGACTGCGTGTG -39,
reverse:
59-TTGAGCGTCCTTGCTTTTCT -39;
FGF-13, forward: 59-GAAATCCAATGCCTGCAAGT-39, re-
verse:
59-AGGTGTGAAATGTTCCGAGG-39;
FGF-14, forward: 59-AGAGCCTGGTTTTTGGGATT-39,
reverse:
59-GTTGACTGGTTTGCCTCCAT-39;
FGF-15, forward: 59-GCTGGTCCCTATGTCTCCAA-39,
reverse:
59-TGGTCCTGGAGCTGTTCTCT-39;
FGF-16, forward: 59-GTCTTTGCCTCCTTGGACTG-39,
reverse:
59-TCTCTCCGAGTCCGAGTGTT-39;
FGF-17, forward: 59- TCAAACACAGGGGGAGAATC-39,
reverse:
59- TCTGCTGCCGAATGTATCTG -39;
FGF-18, forward: 59-GTGCTTCCAGGTTCAGGTGT-39,
reverse:
59-AGCCCACATACCAACCAGAG-39;
FGF-21, forward: 59- CTGGGGGTCTACCAAGCATA -39,
reverse:
59- CAGGATCAAAGTGAGGCGAT -39
FGFR-1b, forward: 59-TTCAGTGGCTGAAGCACATC-39,
reverse:
59-CATGCAGAGTGATGGGAGAG-39;
FGFR-1c, forward: 59-TTCAGTGGCTGAAGCACATC-39,
reverse:
59-GGAAGTCGCTCTTCTTGGTG-39;
FGFR-2b, forward: 59-CTGCCTGGTGGAGAATGAAT-39,
reverse:
59-TCACATTGAACAGAGCCAGC-39;
FGFR-2c, forward: 59-GGAGGGGATGTGGAGTTTGT-39,
reverse:
59-CAGAACTGTCAACCATGCA-39;
FGFR-3b, forward: 59-GGAGTTCCACTGCAAGGTGT-39,
reverse:
59-ACGCAGAGTGATGGGAAAAC-39;
FGFR-3c, forward: 59-GGAGTTCCACTGCAAGGTGT-39,
reverse:
59-CCAGCCTCATCAGTTTCCAT-39;
FGFR-4, forward: 59-CGTGGTCGTCACTGGTACAA-39,
reverse:
59-TGATGGAGGTTAAGGAGTC-39.
Quantitative real-time PCR
RNA of treated and non-treated EBs were extracted on day 3
using Trizol reagent (Invitrogen) according to the manufacturer’s
protocol. RNA was analyzed with quantitative real-time PCR
(qPCR). Melting curve analyses and PCR product sequencing
were performed to verify primer specificities. qRT-PCR was
repeated at least three times using the following conditions. Each
of the reaction mixtures contained 10 ml of SYBR Green master
mix (Applied Biosystems), 5 pmoles each of forward and reverse
primers and 5 ml of 100 times diluted cDNA. The primer
sequences used for qPCR were as follows:
ndrg1, forward: 59-AGTGCACACGTACCGCCAGC-39,r e v e r s e :
59-ACTGGTGTGCGAGCGGCTTC-39;
gsc, forward: 59 -CCAGCAGTGCTCCTGCGTCC-39,r e v e r s e :
59-CCCTCTTCTCCGGCGAGGCT-39;
pdgfrb, forward:59-CACCTTCTCCAGTGTGCTGA-39,r ev e r s e :
59-GGAGTCCATAGGGAGGAAGC-39;
rospo3, forward: 59 -GCTGCCAAGGAGGCTGTGCA-39,
reverse:
59-CGGACCCGTGTTTCAGTCCCC-39;
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reverse:
59- TTGTCCCCTCCACTCTTCAG-39;
nestin, forward: 59 - GCTGGCTGTGGAAGCCCTGG -39,
reverse:
59- CTGGGCACTGTGGCCTCAGC -39;
gata3, forward: 59- CCTGAGCAGCCACCACACCG -39,
reverse:
59- GCAGGCTGCTGGGTGGGAAG -39;
sox17, forward: 59 - TCGACGGCTACCCTCTGCCC -39,
reverse:
59- CGTGCGGTCCACCTCCCCTA -39;
transferrin, forward: 59 - TAAGCTGTCGGAGCCCCGCA -
39, reverse:
59- AAAGGCCACATCCCCACCGC -39;
Cardiomyocyte differentiation quantification by flow
cytometry analysis
Cardiomyocyte differentiation from ES cells or iPS cells was
quantified by flow cytometry (BD FACSCalibur, BD Bioscience,
Bedford, MA) of cardiac specific markers (aMHC promoter-driven
EGFP or cTnT). EBs were collected on day 6 (or as specified
otherwise) and dispersed into single cells by trypsin (Invitrogen).
Cells of ES cell origin were subsequently examined for EGFP
signals. For cells of iPS cell origin, they were first stained with anti-
cTnT antibody (1:100, clone CT3; Developmental Studies
Hybridoma Bank, Iowa City, IA) and Alexa Fluor 568 secondary
antibody (1:1000; Invitrogen) before flow cytometry analysis.
Cardiomyocyte differentiation was quantified by the number of
EGFP positive cells (ES cell-derived cardiomyocytes) or cTnT
positive cells (iPS cell-derived cardiomyocytes). A total of 10000
cells were analyzed at a time and the assay was repeated at least
three times to average the percentage of cardiomyocyte differen-
tiation.
FGF-10 neutralization and FGFR inhibition
For loss-of-function studies, day 2 EBs were cultivated with
FGF-10 neutralizing antibody (BioVision, Mountain View, CA) or
a small-molecule FGFR inhibitor, PD173074 (Sigma, St. Louis,
MO).
Gene knockdown assay
Bacteria transformed with FGF-10, FGFR-1, FGFR-2 shRNA
in pLKO.1-puro lentiviral backbone were obtained from National
RNAi Core Facility (Academia Sinica, Taipei, Taiwan) and
scramble control vector was obtained from Addgene. Further
culture and expansion were conducted according to the manu-
facturer’s protocol. Purified FGF-10, FGFR-1, FGFR-2 shRNA
plasmid was then transfected into 293T cells with Lipofectamine
(Invitrogen) together with an envelope expression plasmid
(pMD2.G) and a packaging vector (psPAX2) to generate the
shRNA-containing lentivirus. Each lentivirus was then infected
into ES cells according to the National RNAi Core Facility
protocol.
Immunohistochemical staining
EBs collected on day 2 to day 7 were fixed, paraffin-embedded,
and subjected to immunohistochemical staining with anti-FGFR-1
antibody (1:100, clone C-15; Santa Cruz Biotechnology, Santa
Cruz, CA) or anti-FGFR-2 antibody (1:100, clone 133730; R&D
Systems), and then with 3,39-diaminobenzidine (DAB) for
visualization (Vector Laboratories, Burlingame, CA).
Cell cycle analysis
ES cells were treated with FGF-10 for 24 h, fixed and subjected
to propidium iodide (1 mg/ml; Sigma) staining and flow
cytometry analysis as previously described [9].
Preparation of a EBs-peptide nanofiber mixture for
transplantation
A mixture of EBs and peptide nanofibers was prepared by
suspending twenty ES cells-derived day 2 EBs into 20 ml of 0.5%
peptide nanofiber (RAD16-II peptide: AcN-RARADADARAR-
ADADA-CNH2, Synpep, Dublin, CA) in phosphate buffered
saline (pH 7.4). FGF-10 (100 ng/ml) or 30 nM PD173074 was
added into the mixture as needed.
In vivo evaluation of FGF-10 on cardiomyocyte
differentiation
C57BL/6 mice (20–25 g, acquired from the National Laboratory
Center, Taipei, Taiwan) were anesthetized with Zoletil (50 mg/kg,
Virbac, France) and Rompun (0.2 ml/kg, Bayer Healthcare,
Germany), artificially ventilated, and had their hearts exposed.
Three groups: 0.5% nanofibers only, 0.5% nanofibers +100 ng/ml
FGF-10, 0.5% nanofibers +100 ng/ml FGF-10+30 nM PD173074,
mixed with day 2 EBs were subsequently injected into the free wall
of left ventricle myocardium by three injections (n=4, in each
group) [32]. The chest was then closed, and the mice were allowed
to recover. Two week later, mice were sacrificed, and the hearts
were harvested, paraformaldehyde-fixed and paraffin-embedded.
Immunohistochemistry was subsequently performed using antibod-
ies against EGFP (1:100, clone 1E4; MBL, Woburn, MA), cTnT
(1:100) and then incubated with Alexa Fluor-conjugated secondary
antibodies (1:200, Molecular probes, Invitrogen). After counter-
staining with DAPI (Sigma-Aldrich), sections were mounted and
observed under a fluorescence microscope. Six sections per heart
were evaluated for ES cell incorporation and EGFP-cTnT double
positive cells were counted and divided by the total cell count.
Microarray analysis
Two-day EBs were treated with or without 100 ng/ml FGF10
and RNA was obtained 24 hours later for microarray analysis,
which were performed by the Affymetrix Gene Expression Service
Lab (http://ipmb.sinica.edu.tw/affy/), supported by the Acade-
mia Sinica. The full normalized data are in Supplementary Data
1. A total of 172 upregulated genes (FGF-10 treatment/without
treatment, p-value ,0.001) were analyzed in MetaCoreTM of
GeneGo Inc. for enrichment of gene ontology terms. Terms with
P values adjusted for multiple testing # 0.01 were considered
enriched. Microarray report conformed to the MIAME guidelines,
and the data was submitted to Gene Expression Omnibus.
Statistical analysis
Results were expressed as mean 6 S.E.M. for at least three
independent experiments. Data were analyzed by Student t-test or
one-way or two-way analysis of variance with Newman-Keuls
post-hoc test where appropriate. Statistical significance was set as
p,0.05 (two-tailed).
Supporting Information
Table S1 Microarray results of gene symbol, accession number,
fold change and predicted functions of the up- and down-
regulated genes in ES cells treated with FGF-10.
Found at: doi:10.1371/journal.pone.0014414.s001 (0.47 MB
XLS)
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differentiation. A, The percentage of cardiomyocyte differentiation
of ES cell treated with FGF-10 over time from day 7 to day 14. B,
the time course study of the three germ layer markers upon FGF-
10 treatment with quantitative real-time PCR.
Found at: doi:10.1371/journal.pone.0014414.s002 (6.68 MB TIF)
Figure S2 The study of ES cell toxicity under the treatment of
FGF receptor inhibitor PD173074. A, Immunoblot analysis of
phospho- and total-Akt in embryoid bodies of different treatment.
FGF-10, 100 ng/ml. Neutralizing antibody, 0.1mg/ml. PD173074,
30 nM. Control, no treatment. B-D, Total cell count of ES cells
treated with an FGF-10 neutralizing antibody, the FGFR inhibitor
PD173074, or a lentivirus contained FGF -10, FGFR-1 or FGFR-
2 shRNA. Control, no treatment.
Found at: doi:10.1371/journal.pone.0014414.s003 (4.26 MB TIF)
Figure S3 Gene expressionprofiles ofEScells treated with FGF-10
p r o t e i no rs h R N A .A ,R T - P C Rr e s u l t ss h o w i n gt h et e m p o r a l
expression pattern of Brachyury, Flk1, Gata4, aMHC, cTnI and
cTnT on day 3 (D3), 5 (D5), 7 (D7) and 9 (D9) during hanging drop
cultivation of ES cells after the treatment of 100 ng/ml FGF-10.
(n§3, *p , 0.05, **p , 0.01, ***p , 0.001.). B, RT-PCR results
showing the temporal expression pattern of Brachyury, Flk1, Gata4,
aM H C ,c T n Ia n dc T n To nd a y3( D 3 ) ,5( D 5 ) ,7( D 7 )a n d9( D 9 )
during hanging drop cultivation of ES cells after FGF-10 knockdown
by shRNA (n§3, *p , 0.05, **p , 0.01, ***p , 0.001.).
Found at: doi:10.1371/journal.pone.0014414.s004 (3.53 MB TIF)
Video S1 Bright field image of control with no treatment
Found at: doi:10.1371/journal.pone.0014414.s005 (1.06 MB AVI)
Video S2 Fluorescence image of control with no treatment
Found at: doi:10.1371/journal.pone.0014414.s006 (0.91 MB AVI)
Video S3 Bright field image of embryoid bodies treated with 100
ng/ml of FGF-10
Found at: doi:10.1371/journal.pone.0014414.s007 (0.96 MB AVI)
Video S4 Fluorescence image of embryoid bodies treated with
100 ng/ml of FGF-10
Found at: doi:10.1371/journal.pone.0014414.s008 (1.39 MB AVI)
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